Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices.
Optimal management of perioperative anticoagulation in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation is not yet established. We performed a meta-analysis of the published literature to assess the safety and efficacy of perioperative heparin-based bridging therapy versus uninterrupted warfarin therapy in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation. We performed a systematic review of MEDLINE (1950 to 2012), EMBASE (1988 to 2012), Cochrane Controlled Trials Register (fourth quarter 2011), and reports presented at scientific meetings (1994 to 2011). Randomized controlled trials, case-control, or cohort studies comparing the safety and efficacy of uninterrupted warfarin therapy to heparin-based bridging therapy were eligible. Outcomes reported in eligible studies were rates of bleeding and thromboembolic events. Of 3,195 reports initially reviewed, we identified 8 studies enrolling 2,321 patients for the meta-analysis. Maintenance of therapeutic warfarin was associated with significantly lower bleeding postoperatively compared to heparin-based bridging therapy (odds ratio 0.30, 95% confidence interval 0.18 to 0.50, p <0.01). There was no significant difference in risk of thromboembolic events between these 2 strategies (odds ratio 0.65, 95% confidence interval 0.14 to 3.02, p = 0.58). In conclusion, strategy of uninterrupted warfarin therapy throughout pacemaker or implantable cardioverter-defibrillator implantation is associated with decreased risk of bleeding without increasing risk of thromboembolic events. This strategy is a viable alternative to heparin-based bridging therapy.
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA. ghhamid@umich.edu
Hamid
H
Ghanbari
Wouter Saint
WS
Phard
Hazim
H
Al-Ameri
Rakesh
R
Latchamsetty
Krit
K
Jongnarngsin
Thomas
T
Crawford
Eric
E
Good
Aman
A
Chugh
Hakan
H
Oral
Frank
F
Bogun
Fred
F
Morady
Frank
F
Pelosi
D000925:Anticoagulants / Q000008:administration & dosage; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D017147:Defibrillators, Implantable; D004305:Dose-Response Relationship, Drug; D014943:Global Health; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D016017:Odds Ratio; D010138:Pacemaker, Artificial; D019919:Prosthesis Implantation / Q000009:adverse effects*; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin